Vitamin K in CKD Bone Disorders.
Maria FusaroG CiancioloP EvenepoelL SchurgersM PlebaniPublished in: Calcified tissue international (2021)
Vitamin K is principally known because it is involved in blood coagulation. Furthermore, epidemiological studies showed that its deficit was associated with increased fragility fractures, vascular calcification and mortality. There are two main types of vitamin K vitamers: Phylloquinone (or PK) and Menaquinones (MKn). Vitamin K acts both as coenzyme of y-glutamyl carboxylase (GGCX) transforming undercarboxylated in carboxylated vitamin K-dependent proteins (e.g., Osteocalcin and Matrix Gla Protein) and as a ligand of the nuclear steroid and xenobiotic receptor (SXR) (in murine species Pregnane X Receptor: PXR), expressed in osteoblasts. It has been highlighted that the uremic state is a condition of greater vitamin K deficiency than the general population with resulting higher prevalence of bone fractures, vascular calcifications and mortality. The purpose of this literature review is to evaluate the protective role of Vitamin K in bone health in CKD patients.
Keyphrases
- replacement therapy
- chronic kidney disease
- end stage renal disease
- bone mineral density
- risk factors
- cardiovascular events
- soft tissue
- bone loss
- ejection fraction
- newly diagnosed
- bone regeneration
- public health
- healthcare
- peritoneal dialysis
- postmenopausal women
- binding protein
- mental health
- case report
- body composition
- health information
- type diabetes
- cardiovascular disease
- patient reported